Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHEMO-IMMUNE THERAPY

Financiado

Cerrado

A translational approach evaluating novel strategies using chemotherapy to enhan...

A translational approach evaluating novel strategies using chemotherapy to enhance immune mediated anti tumor activity A wealth of successful pre-clinical immunotherapy-based treatment protocols against cancer have been documented, yet only a limited number of clinical trials have proven to be successful. A common consensus among clinical and benc... ver más

31/10/2013

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CAR-T-uning Chimeric Antigen Receptor (CAR) T Cell Therapy For Solid Tum... 150K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

NEXIM A Next generation targeted immuno oncology therapy 71K€ Cerrado

NextGen IO Exploiting the hypoxia response in T cells for Next Generati... 2M€ Cerrado

T-RAFIC Training network for tracking and controlling therapeutic im... Cerrado

TIL-FIT Increasing the fitness of tumor infiltrating T cells for cel... 1M€ Cerrado

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto A wealth of successful pre-clinical immunotherapy-based treatment protocols against cancer have been documented, yet only a limited number of clinical trials have proven to be successful. A common consensus among clinical and bench-side researchers is that a combination of several treatment modalities should be used to achieve complete tumor regression. In recent years, evidence that chemotherapy agents can be used to enhance immune-based therapies has emerged. The specific aims described below are designed to evaluate novel treatment modalities against cancer using chemotherapy agents that have the ability to sensitize tumors to both innate and adaptive anti-tumor immune responses. 1. Examine the effect of different chemotherapy agents in their ability to modify tumor susceptibility to autologous and allogeneic natural killer (NK) and T cell -mediated apoptosis in vitro. 2. In vivo confirmation and evaluation of selected agents in murine syngeneic and allogeneic hematopoietic stem cell transplantation (HCT) tumor models. The results of these studies will lay a foundation for NK cell-based and T cell-based therapies which could lead to more effective treatments for cancer patients. In addition to defining mechanisms how the various chemotherapy agents may influence NK or T cell anti-tumor responses, several subsidiary projects derived from this research will most likely develop.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores